Cash Flow Statement

Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt repayments

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization EBIAT Leases Long-Term Debt Issuances Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Receivables Refunds Shares Issued Shares Outstanding Shares Outstanding Short-Term Debt repayments

Barinthus Biotherapeutics (BRNS) Preferred Shares Issued (2021)

Barinthus Biotherapeutics filings provide 1 years of Preferred Shares Issued readings, the most recent being $125.2 million for Q1 2021.

On a quarterly basis, Preferred Shares Issued changed N/A to $125.2 million in Q1 2021 year-over-year; TTM through Dec 2021 was $125.2 million, a N/A change, with the full-year FY2021 number at $125.2 million, changed N/A from a year prior.
Preferred Shares Issued hit $125.2 million in Q1 2021 for Barinthus Biotherapeutics.
In the past five years, Preferred Shares Issued ranged from a high of $125.2 million in Q1 2021 to a low of $125.2 million in Q1 2021.